68Ga-radiolabeled AGuIX nanoparticles as dual-modality imaging agents for PET/MRI-guided radiation therapy.
Nanomedicine (Lond)
; 12(13): 1561-1574, 2017 Jul.
Article
em En
| MEDLINE
| ID: mdl-28621567
ABSTRACT
AIM:
The aim of this study was to develop a dual-modality positron emission tomography/magnetic resonance (PET/MR) imaging probe by radiolabeling gadolinium-containing AGuIX derivatives with the positron-emitter Gallium-68 (68Ga). MATERIALS &METHODS:
AGuIX@NODAGA nanoparticles were labeled with 68Ga at high efficiency. Tumor accumulation in an appropriate disease model was assessed by ex vivo biodistribution and in vivo PET/MR imaging.RESULTS:
68Ga-AGuIX@NODAGA was proven to passively accumulate in U87MG human glioblastoma tumor xenografts. Metabolite assessment in serum, urine and tumor samples showed that 68Ga-AGuIX@NODAGA remains unmetabolized up to at least 60 min postinjection.CONCLUSION:
This study demonstrates that 68Ga-AGuIX@NODAGA can be used as a dual-modality PET/MR imaging agent with passive accumulation in the diseased area, thus showing great potential for PET/MR image-guided radiation therapy.Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Siloxanas
/
Neoplasias do Sistema Nervoso Central
/
Glioblastoma
/
Meios de Contraste
/
Nanopartículas
/
Complexos de Coordenação
/
Radioisótopos de Gálio
/
Compostos Heterocíclicos com 1 Anel
/
Acetatos
Limite:
Animals
/
Female
/
Humans
Idioma:
En
Ano de publicação:
2017
Tipo de documento:
Article